reported three types of SNAs that are compositionally identical yet structurally distinct from cancer vaccines.[173] They all share a liposome core, a shell of CpG oligonucleotides as agonists of TLR9, and OVA‐1 peptides as antigens. Here, TLR9 is linked to cancer.